Palatin Technologies Inc. | Ownership
Companies that own Palatin Technologies Inc.
BlackRock Fund Advisors
9,312,033
4.62%
8,087,049
0%
06/30/2018
The Vanguard Group, Inc.
8,482,351
4.21%
946,396
0%
06/30/2018
Acadian Asset Management LLC
3,246,810
1.61%
-68,342
0.01%
06/30/2018
SSgA Funds Management, Inc.
2,679,255
1.33%
2,610,716
0%
06/30/2018
Geode Capital Management LLC
2,476,391
1.23%
1,460,694
0%
06/30/2018
Northern Trust Investments, Inc.
2,082,532
1.03%
1,749,255
0%
06/30/2018
Arrowstreet Capital LP
1,370,214
0.68%
169,300
0%
06/30/2018
Renaissance Technologies LLC
1,252,770
0.62%
-1,492,959
0%
06/30/2018
Ativo Capital Management LLC
1,100,338
0.55%
1,100,338
0.26%
06/30/2018
Bridgeway Capital Management, Inc.
796,000
0.4%
250,000
0.01%
06/30/2018
| Address |
Cedar Brook Corporate Center
Cranbury New Jersey 08512
United States
|
|
Employees
|
- |
| Website |
http://www.palatin.com |
| Updated |
07/08/2019 |
| Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. |
